Drug prices: How do we get to a better place?
- PMID: 28606974
- PMCID: PMC5468102
- DOI: 10.1503/cmaj.170440
Drug prices: How do we get to a better place?
Conflict of interest statement
Competing interests: In 2015/16, Joel Lexchin received payment from two nonprofit organizations as a consultant on one project that dealt with indication-based prescribing, and a second on which drugs should be distributed free of charge by general practitioners. In 2015, he received payment from a for-profit organization for participation on a panel that discussed expanding drug insurance in Canada. He is on the Foundation Board of Health Action International.
Comment on
-
Drivers of expenditure on primary care prescription drugs in 10 high-income countries with universal health coverage.CMAJ. 2017 Jun 12;189(23):E794-E799. doi: 10.1503/cmaj.161481. CMAJ. 2017. PMID: 28606975 Free PMC article.
References
-
- Grant K. Rare public hearing highlights concerns over explosion of high-priced specialty drugs in Canada. Globe and Mail [Toronto]. 2017. January 15 Available: www.theglobeandmail.com/news/national/rare-public-hearing-highlights-con... (accessed 2017 Jan. 20).
-
- Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001;285:421–9. - PubMed
-
- Canadian pharmaceutical industry review 2015. Montréal: imshealth | brogan; 2016. Available: http://imsbrogancapabilities.com/YIR_2015_FINAL (accessed 2016 Oct. 10).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources